FindTrial
Sign In

Clinical study on screening and validation of biomarkers for hyperlipidemia with phlegm turbidity and internal obstruction syndrome based on metabolomics

Clinical study on screening and validation of biomarkers for hyperlipidemia with phlegm turbidity and internal obstruction syndrome based on metabolomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025002094
Enrollment
Unknown
Registered
2025-10-28
Start date
2024-09-12
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemias phlegm-turbidity internal obstruction syndrome

Interventions

Hyperlipidemias phlegm-turbidity internal obstruction syndrome group:None
Hyperlipidemias are not syndrome of phlegm-turbidity internal obstruction group:None
Healthy controls:None

Sponsors

The First Affiliated Hospital of Henan University of CM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for primary hyperlipidemia; 2.Meets the diagnostic criteria for phlegm turbidity internal obstruction syndrome; 3.Those who voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe liver and kidney dysfunction; 2.Those with active hepatitis and continuous elevated transaminases cannot be explained; 3.Patients with a history of hemorrhagic disease or hemophilia; 4.Patients with mental illness; 5.Pregnant and lactating women; 6.The researchers believe that other reasons are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
metabolome;—

Countries

China

Contacts

Public ContactWang Xin-lu

The First Affiliated Hospital of Henan University of CM

wangxinlu110@126.com15038352207

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026